Mutation of the KRAS gene in the A549 cell line [60] may contribute to this observation, as indicated by a study that showed the treatment of 5-FU might preferentially sensitize KRAS-mutated NSCLC samples to TRAIL-induced apoptosis [61]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.